TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16584341

Group type: EXPERIMENTAL
Intervention: Scaling and root planing followed by local application of doxycycline (SRP-D)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 48
Study: 14535875

Group type: EXPERIMENTAL
Intervention: RBCAT (ranitidine bismuth citrate 400 mg b.d. plus amoxicillin 1 g b.d. and tinidazole 500 mg b.d.)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PAL (pantoprazole 40 mg b.d. plus amoxicillin 1 g b.d. and levofloxacin 500 mg/day)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PBTM (pantoprazole 40 mg b.d., bismuth citrate 240 mg b.d., tetracycline 500 mg q.d.s. and metronidazole 500 mg b.d.)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PBTM
Number of subjects: 180
Study: 11899411

Group type: EXPERIMENTAL
Intervention: Dissection/snare technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Suction-cautery technique
Number of subjects: 50
Study: 9771208

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate and calcitriol (E + C)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cyclical etidronate (E)
Number of subjects: 47
Study: 8116547

Group type: EXPERIMENTAL
Intervention: Monounsaturated rapeseed oil diet
Number of subjects: 95

Group type: COMPARATOR
Intervention: Sunflower oil diet
Number of subjects: 95
Study: 3294020

Group type: EXPERIMENTAL
Intervention: bepridil 900 mg followed by 300 mg daily for 11 days
Number of subjects: 37
Study: 1603890

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg (active drug)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 21
Study: 373778

Group type: EXPERIMENTAL
Intervention: Secretolytic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Respirophonography
Number of subjects: 0
Study: 31264286

Group type: EXPERIMENTAL
Intervention: Experimental group (instructed to increase stride-rate by 10% using a watch and foot pod for feedback)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (instructed to continue normal running)
Number of subjects: 38
Study: 28350328

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU of oral VitD3 once weekly for 8 weeks)
Number of subjects: 68
Study: 27701025

Group type: EXPERIMENTAL
Intervention: Nurse led telephone supportive care programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study: 24929429

Group type: EXPERIMENTAL
Intervention: Closed-loop control (CLC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open-loop (OL) sensor-augmented insulin pump therapy
Number of subjects: 20
Study: 21941187

Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 214

Group type: COMPARATOR
Intervention: Standard sedation with benzodiazepines and opioids
Number of subjects: 214
Study: 19441980

Group type: EXPERIMENTAL
Intervention: Amphotericin B 0.7 mg/kg plus fluconazole 800 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Amphotericin B 0.7 mg/kg plus fluconazole 400 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Amphotericin B 0.7 mg/kg (standard therapy)
Number of subjects: 143
Study: 17690547

Group type: EXPERIMENTAL
Intervention: rt‐PA
Number of subjects: 615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study: 15161435

Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta®) plus cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta®) with vitamin B12 and folate supplementation
Number of subjects: 0
Study: 11943793

Group type: EXPERIMENTAL
Intervention: New South Wales mammographic screening programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised trials of screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Service studies
Number of subjects: 0
Study: 9827927

Group type: EXPERIMENTAL
Intervention: VAD (vincristine, doxorubicin, dexamethasone)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: VMBCP (vincristine, BCNU, cyclophosphamide, melphalan and prednisone)
Number of subjects: 263

Group type: COMPARATOR
Intervention: VAD
Number of subjects: 263

Group type: COMPARATOR
Intervention: VMBCP
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Both VAD and VMBCP
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Karnofsky index > 60 and albuminaemia > or = 34 g/l
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Karnofsky index < or = 60 and albuminaemia < 34 g/l
Number of subjects: 263
Study: 8015506

Group type: EXPERIMENTAL
Intervention: Klimaxil (17 beta‐estradiol 2 mg and medroxy‐progesterone acetate 5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Divina (17 beta‐estradiol valerate 2 mg and medroxyprogesterone acetate 10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trisequence (17 beta‐estradiol 2 mg in the first phase) and Provera (medroxyprogesterone acetate 5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 12
Study: 2816769

Group type: EXPERIMENTAL
Intervention: Epicardial color Doppler echocardiography
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transesophageal color Doppler echocardiography
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transesophageal color flow mapping
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Epicardial color flow mapping
Number of subjects: 22
Study: 2110

Group type: EXPERIMENTAL
Intervention: Intra-nasal beclomethasone dipropionate (400 mug/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 18
Study: 31237318

Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study: 28377342

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Common balloon (CB)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 25311593

Group type: EXPERIMENTAL
Intervention: Daclatasvir 12 weeks (60 mg once daily) + peginterferon alfa-2a + ribavirin
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Daclatasvir 16 weeks (60 mg once daily) + peginterferon alfa-2a + ribavirin
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo + peginterferon alfa-2a + ribavirin
Number of subjects: 151
Study: 24054755

Group type: EXPERIMENTAL
Intervention: Transatrial-transpulmonary approach (Group A)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Transventricular approach (Group B)
Number of subjects: 106
Study: 21632064

Group type: EXPERIMENTAL
Intervention: St. John's Wort (810 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18838245

Group type: EXPERIMENTAL
Intervention: Sentinel Node (SN) biopsy only
Number of subjects: 150

Group type: COMPARATOR
Intervention: Axillary Lymph Node Dissection (ALND)
Number of subjects: 150
Study: 16876451

Group type: EXPERIMENTAL
Intervention: Orange juice and 0.5 g MCT per kg lean body mass
Number of subjects: 9

Group type: COMPARATOR
Intervention: Orange juice alone
Number of subjects: 9
Study: 15702625

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors, CCBs, and conventional treatment (diuretics/beta-blockers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure lowering treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimens based on different drug classes
Number of subjects: 0
Study: 10687323

Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) 0.3 mg/day for 3 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Scopolamine butylbromide (SB) 60 mg/day for 3 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Parenteral hydration
Number of subjects: 17

Group type: COMPARATOR
Intervention: Less parenteral hydration
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pain relief treatment
Number of subjects: 17
Study: 9352972

Group type: EXPERIMENTAL
Intervention: 8 weeks of knee extensor endurance training
Number of subjects: 16
Study: 1363053

Group type: EXPERIMENTAL
Intervention: Bupivacaine (high concentration, 5 mg/ml; low concentration, 2.5 mg/ml) with volumes of 15-20 ml (high) or 5-10 ml (low) injected at C6 or C7
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Injection toward C7 instead of C6
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High concentration of bupivacaine instead of low concentration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Volume of bupivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pre-block skin temperature
Number of subjects: 30
Study: 3898351

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg twice daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 55
Study: 30878612

Group type: EXPERIMENTAL
Intervention: Cupping treatment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Benzodiazepine treatment
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 67
Study: 29239893

Group type: EXPERIMENTAL
Intervention: dolutegravir with rilpivirine
Number of subjects: 81

Group type: COMPARATOR
Intervention: current ART
Number of subjects: 81
Study: 28145966

Group type: COMPARATOR
Intervention: 0 cm H2O PEEP
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 5 cm H2O PEEP
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 10 cm H2O PEEP
Number of subjects: 105
Study: 26637993

Group type: EXPERIMENTAL
Intervention: Cardiovascular seven‐faceted screening examinations including low‐dose non‐contrast CT scan, brachial and ankle blood pressure index, telemetric assessment of heart rhythm, cholesterol and plasma glucose measurement.
Number of subjects: 45000

Group type: COMPARATOR
Intervention: Control group (no screening).
Number of subjects: 45000
Study: 23924453

Group type: EXPERIMENTAL
Intervention: Modified lamina replantation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Traditional laminectomy replantation
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both groups (Modified and Traditional)
Number of subjects: 124
Study: 20878375

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (SCPB) with 20 mL of a 1:1 mixture of 0.5% bupivacaine and 2% lidocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Morphine 0.1 mg·kg⁻¹ iv after dural closure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 18420853

Group type: EXPERIMENTAL
Intervention: Haloperidol plus ondansetron
Number of subjects: 268

Group type: COMPARATOR
Intervention: Ondansetron alone (saline control)
Number of subjects: 268
Study: 16647354

Group type: EXPERIMENTAL
Intervention: Early drain removal on postoperative day 2
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard drain removal (< 30 mL drainage in 24 hours or postoperative day 14)
Number of subjects: 27
Study: 12952111

Group type: EXPERIMENTAL
Intervention: Attendance at study visits
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Study dropout
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Factors associated with missed visits
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Characteristics of study dropouts
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Attendance patterns
Number of subjects: 1041
Study: 10372699

Group type: COMPARATOR
Intervention: GnRHa treatment only (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GnRHa for 12 months followed by calcium supplementation (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined GnRHa and calcium from the beginning (Group C)
Number of subjects: 40
Study: 8720819

Group type: EXPERIMENTAL
Intervention: Computer-based medical teaching (CBMT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no CBMT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control test (not related to CBMT)
Number of subjects: 103
Study: 1679252

Group type: EXPERIMENTAL
Intervention: Alternative somatic treatments for schizophrenia
Number of subjects: 0
Study: 7237025

Group type: EXPERIMENTAL
Intervention: DDAVP (1 deamino‐8‐D‐arginine vasopressin) at a dose of 1 microgram
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: DDAVP (1 deamino‐8‐D‐arginine vasopressin) at a minimum effective dose of 2 ng/kg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: DDAVP (1 deamino‐8‐D‐arginine vasopressin)
Number of subjects: 2
Study: 30784208

Group type: EXPERIMENTAL
Intervention: PF‐04895162 (300 mg twice daily for 2 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PF‐04895162
Number of subjects: 8
Study: 28106903

Group type: EXPERIMENTAL
Intervention: Rd continuous (lenalidomide plus low-dose dexamethasone)
Number of subjects: 114

Group type: COMPARATOR
Intervention: MPT (melphalan, prednisone, thalidomide)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Rd18 (lenalidomide plus low-dose dexamethasone for 18 cycles)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Rd continuous
Number of subjects: 114
Study: 25534959

Group type: EXPERIMENTAL
Intervention: Nevasic plus usual care
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Music plus usual care
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 99
Study: 24297841

Group type: EXPERIMENTAL
Intervention: 15 mg/kg racemic ketamine (Keta‐Race)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 9 mg/kg S‐ketamine (S‐Keta)
Number of subjects: 28
Study: 21272715

Group type: EXPERIMENTAL
Intervention: Vibratory stimuli applied to the plantar region
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 30
Study: 19616440

Group type: EXPERIMENTAL
Intervention: Clopidogrel discontinued 5 days prior to surgery (group 1)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Clopidogrel discontinued 3 days prior to surgery (group 2)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Clopidogrel discontinued on the day of surgery (group 3)
Number of subjects: 130
Study: 16513614

Group type: EXPERIMENTAL
Intervention: Helical dynamic CT (HDCT)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Integrated PET/CT
Number of subjects: 119
Study: 12607287

Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment for 12 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment for 6 weeks
Number of subjects: 18
Study: 10691121

Group type: EXPERIMENTAL
Intervention: Monitoring group (serum AED concentration adjusted to target range)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (dosage adjusted on clinical grounds)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Monitoring group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 8462190

Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate (TU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3942703

Group type: EXPERIMENTAL
Intervention: In-out urethral catheter
Number of subjects: 50

Group type: COMPARATOR
Intervention: Indwelling urethral catheter
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 29160598

Group type: EXPERIMENTAL
Intervention: Vortioxetine (5-20 mg/day)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study: 27525817

Group type: EXPERIMENTAL
Intervention: Ma-Pi diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 24950720

Group type: EXPERIMENTAL
Intervention: AirSeal (group A)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard CO₂ pressure insufflator (group S)
Number of subjects: 182
Study: 22378321

Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous and postoperative oral clindamycin for 7 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 120
Study: 20360919

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (Group I)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Surgical procedures for abdominal wall hernia (Group II)
Number of subjects: 2
Study: 18599520

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15682483

Group type: EXPERIMENTAL
Intervention: LAM (lamivudine) taken by 10 patients with YMDD mutations
Number of subjects: 104

Group type: COMPARATOR
Intervention: YMDD mutations in patients with chronic hepatitis B
Number of subjects: 104

Group type: COMPARATOR
Intervention: HBV DNA level
Number of subjects: 104

Group type: COMPARATOR
Intervention: HBeAg positive and negative cases
Number of subjects: 104
Study: 12430637

Group type: EXPERIMENTAL
Intervention: Outreach intervention involving home visits by outreach workers and group meetings in neighborhood settings.
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 370
Study: 10598660

Group type: EXPERIMENTAL
Intervention: CI-980 at 3.5 mg/m2/day for 3 days (continuous intravenous infusion)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CI-980 at 4.2 mg/m2/day with G-CSF (for brain tumor patients)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CI-980 at 5 mg/m2/day with G-CSF (for solid tumor patients)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CI-980 at 5 mg/m2/day regimen
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CI-980
Number of subjects: 33
Study: 8773913

Group type: EXPERIMENTAL
Intervention: Bleeding time
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Previous bleeding, liver failure, and variceal size
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Severity of liver failure and variceal size
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gastrointestinal bleeding
Number of subjects: 80
Study: 1425821

Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy (Group 1)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Early combination of bromocriptine and levodopa (Group 2A)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Levodopa alone (Group 2B)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 702
Study: 6539877

Group type: EXPERIMENTAL
Intervention: Verapamil HCl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31651453

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Number of subjects: 3071

Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 3071
Study: 30021625

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 ng/mL (group R2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil 4 ng/mL (group R4)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil 6 ng/mL (group R6)
Number of subjects: 120
Study: 26543061

Group type: EXPERIMENTAL
Intervention: Prefabricated functional appliance (PFA)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Slightly modified Andresen activator (AA)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both PFA and AA
Number of subjects: 97
Study: 24485052

Group type: EXPERIMENTAL
Intervention: Biodegradable screws
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional metal plates
Number of subjects: 54
Study: 22708521

Group type: EXPERIMENTAL
Intervention: Supervising for Home Safety program (content focused on child‐injury risks and supervision needs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (content focused on child nutrition and exercise)
Number of subjects: 0
Study: 20375791

Group type: EXPERIMENTAL
Intervention: HPV-16 E6 European variants
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Mixed variants of HPV-16 infections
Number of subjects: 106
Study: 18586813

Group type: EXPERIMENTAL
Intervention: Interdisciplinary programme (physiotherapy, occupational therapy, physical education)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Physiotherapist alone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Interdisciplinary programme
Number of subjects: 54
Study: 15704053

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg 3 times daily
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 11805349

Group type: EXPERIMENTAL
Intervention: L‐adrenaline (0.1ml/kg/dose in 1 in 10,000 solution)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Salbutamol (0.1mg/kg/dose)
Number of subjects: 91
Study: 10369063

Group type: EXPERIMENTAL
Intervention: Individualized relapse prevention (RP)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard group counseling (STND)
Number of subjects: 132
Study: 8749227

Group type: EXPERIMENTAL
Intervention: Methylcobalamin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methylcobalamin + Steroid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Steroid
Number of subjects: 60
Study: 1386825

Group type: EXPERIMENTAL
Intervention: Fish oil containing eicosapentaenoic acid (4.1 g/day) and docosahexaenoic acid (3.6 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6837242

Group type: EXPERIMENTAL
Intervention: 4% gelatine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 6% dextran
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (mean molecular weight 40,000 or 125,000)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Balanced salt solution and glucose
Number of subjects: 132
Study: 30644740

Group type: EXPERIMENTAL
Intervention: Citrus sinensis cv. 'Cara Cara' orange juice (500 mL daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citrus sinensis cv. 'Bahia' orange juice (500 mL daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric control drink
Number of subjects: 0
Study: 29336387

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 mcg/kg loading dose over 15 minutes, followed by 0.5 mcg/kg/h maintenance infusion for 2 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (same volume as dexmedetomidine)
Number of subjects: 60
Study: 26553461

Group type: EXPERIMENTAL
Intervention: Multidisciplinary nutritional support
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no multidisciplinary nutritional support)
Number of subjects: 95